Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 229

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 229
---
, the number of shares underlying the Representative’s Warrants shall be reduced if necessary to comply with FINRA rules
or regulations.

<div align='center'>136</div>

The Representative’s
Warrants are deemed underwriter compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(e)(1)(A).
The Representative (or permitted assignees under Rule 5110(e)(1)(A)) will not sell, transfer, assign, pledge, or hypothecate these warrants
or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the warrants or the underlying securities for a period of 180 days from commencement
of sales in this offering. In addition, the Representative’s Warrants provide for registration rights upon request, in certain
cases. The one-time demand registration right provided will not be greater than five years from the commencement of sales of this offering
in compliance with FINRA Rule 5110(g)(8)(C). The piggyback registration right provided will not be greater than seven years from the
commencement of sales of this offering in compliance with FINRA Rule 5110(g)(8)(D). We will bear all fees and expenses attendant to registering
the securities issuable on exercise of the Representative’s Warrants other than underwriting commissions incurred and payable by
the holders. The exercise price and number of shares issuable upon exercise of the Representative’s Warrants may be adjusted in
certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger, or consolidation. However,
neither the Representative Warrant exercise price, nor the number of Ordinary Shares underlying such warrants, will be adjusted for issuances
of Ordinary Shares by us at a price below the exercise price of the Representative’s Warrants.

Discretionary Accounts

The underwriters do not intend
to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.

Lock-Up Agreements

Pursuant to certain
“lock-up” agreements, we, our executive officers and directors and substantially all of the current holders of our
Ordinary Shares or securities convertible into Ordinary Shares, will agree, for a period of twelve (12) months from the closing of
this offering, with respect to our directors and executive officers and for a period of six (6) months from the closing of this